Picture this: a medicine targeting a particular disease is developed over 12-15 years from initial candidate selection, ...

Wherever you sit in the partnership triangle, does it sound familiar? Many initiatives have tried to address this partnership ...

Sanofi has shared positive results from a late-stage study of its investigational BTK inhibitor, tolebrutinib, in patients ...

Novo Nordisk and NanoVation Therapeutics have entered into a multi-year partnership worth $600m to advance genetic medicines ...

The essence of omnichannel marketing is to ensure that your messaging is reaching your target audience where they spend most ...

The European Commission (EC) has extended the marketing authorisation for Bavarian Nordic’s smallpox and mpox vaccine to ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for certain cases of acute myeloid leukaemia (AML). The drug has been ...

Wedgewood Communications has appointed Danielle Cranwell as president and global agency head to lead the evolution of the agency’s strategic vision and future direction. Cranwell brings more than two ...

Researchers from the Wellcome Sanger Institute have discovered that a common diabetes medication can slow the growth of precancerous cells in the oesophagus. The findings published in Nature Genetics ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food and Drug Administration (FDA) for multiple cancer types. The subcutaneous ...

Roche’s injectable monoclonal antibody Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) has been approved by the US Food and Drug Administration (FDA) to treat both relapsing and primary ...